Breast Cancer Research and Treatment

, Volume 121, Issue 2, pp 431–437

Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia

  • Marta Santisteban
  • Carol Reynolds
  • Emily G. Barr Fritcher
  • Marlene H. Frost
  • Robert A. Vierkant
  • Stephanie S. Anderson
  • Amy C. Degnim
  • Daniel W. Visscher
  • V. Shane Pankratz
  • Lynn C. Hartmann
Epidemiology

DOI: 10.1007/s10549-009-0534-7

Cite this article as:
Santisteban, M., Reynolds, C., Barr Fritcher, E.G. et al. Breast Cancer Res Treat (2010) 121: 431. doi:10.1007/s10549-009-0534-7

Abstract

Uncontrolled proliferation is a defining feature of the malignant phenotype. Ki67 is a marker for proliferating cells and is overexpressed in many breast cancers. Atypical hyperplasia is a premalignant lesion of the breast (relative risk ~ 4.0). Here, we asked if Ki67 expression could stratify risk in women with atypia. Ki67 expression was assessed immunohistochemically by digital image analysis in archival sections from 192 women with atypia diagnosed at the Mayo Clinic 1/1/67–12/31/91. Risk factor and follow-up data were obtained via study questionnaire and medical records. Observed breast cancer events were compared to population expected rates (Iowa SEER) using standardized incidence ratios (SIRs). We examined two endpoints: risk of breast cancer within 10 years and after 10 years of atypia biopsy. Thirty-two (16.7%) of the 192 women developed breast cancer over a median of 14.6 years. Thirty percent (58) of the atypias had ≥2% cells staining for Ki67. In these women, the risk of breast cancer within 10 years after atypia was increased (SIR 4.42 [2.21–8.84]) but not in those with <2% staining. Specifically, the cumulative incidence for breast cancer at 10 years was 14% in the high Ki67 vs. 3% in the low Ki67 group. Conversely, after 10 years, risk in the low Ki67 group rose significantly (SIR 5.69 [3.63–8.92]) vs. no further increased risk in the high Ki67 group (SIR 0.78 [0.11–5.55]). Ki67 appears to be a time-varying biomarker of risk of breast cancer in women with atypical hyperplasia.

Keywords

Atypical hyperplasia Breast cancer risk Ki-67 Immunohistochemistry 

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Marta Santisteban
    • 1
  • Carol Reynolds
    • 2
  • Emily G. Barr Fritcher
    • 2
  • Marlene H. Frost
    • 3
  • Robert A. Vierkant
    • 4
  • Stephanie S. Anderson
    • 4
  • Amy C. Degnim
    • 5
  • Daniel W. Visscher
    • 6
  • V. Shane Pankratz
    • 4
  • Lynn C. Hartmann
    • 3
  1. 1.Department of OncologyClinica Universitaia de NavarraNavarraSpain
  2. 2.Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Mayo Graduate School of Medical EducationMayo Clinic College of MedicineRochesterUSA
  3. 3.Division of Medical Oncology, Department of Oncology, Mayo Clinic Cancer Center, Mayo Graduate School of Medical EducationMayo Clinic College of MedicineRochesterUSA
  4. 4.Department of Health Sciences Research—Biostatistics, Mayo Clinic Cancer Center, Mayo Graduate School of Medical EducationMayo Clinic College of MedicineRochesterUSA
  5. 5.Department of General Surgery, Mayo Clinic Cancer Center, Mayo Graduate School of Medical EducationMayo Clinic College of MedicineRochesterUSA
  6. 6.Department of PathologyUniversity of MichiganAnn ArborUSA

Personalised recommendations